# MNKD catalysts: MANNKIND CORP PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mnkd/catalysts

> MANNKIND CORP (MNKD) has 4 upcoming catalysts. The next is the technosphere insulin primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MANNKIND CORP |
| Ticker | MNKD (Nasdaq) |
| SEC CIK | 899460 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mnkd |

## Cash runway

Cash $96.6M as of 2026-09-30; quarterly burn $34.5M; about 8.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-449776).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [Clofazimine trial start](https://sec-api.dev/pdufa/clofazimine) | MNKD |  | completed | "In June 2024, we initiated a Phase 3 clinical study of MNKD-101, with sites in the United States, Japan, South Korea, Taiwan and Australia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/899460/000095017025027735/mnkd-20241231.htm)) |
| February 26, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "February 26, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025027721/mnkd-ex99_1.htm)) |
| mid-2025 | [Afrezza (afrezza) NDA/BLA submission](https://sec-api.dev/pdufa/afrezza) | MNKD |  | scheduled | "Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-ex99_1.htm)) |
| Q2 2025 | [MANNKIND CORP topline data readout](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | scheduled | "Topline results from the full study pediatric data set with the safety extension expected in 2Q 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-ex99_1.htm)) |
| May 8, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "May 8, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025066426/mnkd-ex99_1.htm)) |
| Q3 2025 | [V-Go (v-go) NDA/BLA submission](https://sec-api.dev/pdufa/v-go) | MNKD |  | scheduled | "Diversified revenue base with three commercial assets in Afrezza, V-Go®, and now FUROSCIX Combined with Tyvaso DPI-related revenues, annualized run rate of over $370M based on Q2 2025 results Accelerate double-digit annual growth with potential to expand market reach Strong commercial momentum with 2024 sales force expansion, ongoing launch into nephrology and accelerating growth in integrated delivery networks Net sales of $27.8M for H1 2025, up 96% year-over-year ReadyFlow Autoinjector on track for Q3 2025 sNDA submission, potentially unlocking additional market opportunity Diversification and Acceleration of Revenue Strategic Fit Strong FUROSCIX Sales Momentum" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701dex992.htm)) |
| Q3 2025 | [Furosemide NDA/BLA submission](https://sec-api.dev/pdufa/furosemide) | MNKD |  | scheduled | "FUROSCIX ReadyFlow Autoinjector on track for Q3 2025 sNDA submission, potentially unlocking additional market opportunity" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701dex991.htm)) |
| August 6, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "August 6, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/mnkd-ex99_1.htm)) |
| late 2025 | [Ofev® (nintedanib) trial start](https://sec-api.dev/pdufa/nintedanib) | MNKD |  | scheduled | "In addition to established marketed products, MannKind is advancing a late-stage pipeline that includes Inhaled Clofazimine (MNKD-101), which is currently in a phase 3 global study for nontuberculous mycobacterial (NTM) lung disease, and nintedanib DPI (MNKD-201), which is expected to initiate a phase 2 clinical trial for IPF by year-end 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525186994/d931701dex991.htm)) |
| Oct 2025 | [Afrezza (afrezza) NDA/BLA acceptance](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed | "In October 2025, the FDA accepted for review a supplemental BLA for Afrezza in children and adolescents between the ages of 4-17 who are living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/mnkd-20260527.htm)) |
| November 5, 2025 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "November 5, 2025 (Globe Newswire) — MannKind Corporation (Nasdaq: MNKD) today reported financial results for the third quarter of 2025 and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| November 10, 2025 | [Clofazimine inhalation suspension primary completion](https://sec-api.dev/pdufa/clofazimine-inhalation-suspension) | MNKD |  | withdrawn | "NCT06418711 (ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06418711)) |
| 2026 | [Clofazimine interim data readout](https://sec-api.dev/pdufa/clofazimine) | MNKD |  | scheduled | "MNKD-101 (nebulized) Phase 3 global clinical trial for the treatment of NTM (ICoN-1) achieved interim enrollment target of 100 patients ahead of schedule; interim analysis (study sample size re-estimation) expected mid-year 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| January 23, 2026 | [Afrezza (insulin recombinant human) label expansion decision](https://sec-api.dev/pdufa/insulin-recombinant-human) | MNKD |  | completed, approved | "BLA022472 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260123, review_priority STANDARD; sponsor_name MANNKIND; product AFREZZA (INSULIN RECOMBINANT HUMAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA022472%22)) |
| February 26, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm)) |
| May 6, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm)) |
| May 29, 2026 | [Afrezza (afrezza) FDA approval](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed, approved | "Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-ex99_1.htm)) |
| May 29, 2026 | [Afrezza (afrezza) PDUFA date](https://sec-api.dev/pdufa/afrezza) | MNKD |  | completed, approved | "o sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026 o" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312525265810/mnkd-ex99_1.htm)) |
| May 29, 2026 | [MANNKIND CORP PDUFA date](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | scheduled | "The sBLA has been assigned a PDUFA target action date of May 29, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/899460/000119312526208916/mnkd-20260331.htm)) |
| May 29, 2026 | [Afrezza (insulin recombinant human) label expansion decision](https://sec-api.dev/pdufa/insulin-recombinant-human) | MNKD |  | completed, approved | "BLA022472 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260529, review_priority STANDARD; sponsor_name MANNKIND; product AFREZZA (INSULIN RECOMBINANT HUMAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA022472%22)) |
| Q3 2026 | [Ofev® (nintedanib) topline data readout](https://sec-api.dev/pdufa/nintedanib) | MNKD |  | scheduled | "We are currently conducting a Phase 1b study of MNKD-201 in the United States, with top line data expected in the third quarter of 2026, as well as a global Phase 2 study to assess the potential safety and efficacy of this investigational product in patients with IPF, in which we expect the first patient to be enrolled in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/899460/000119312526208916/mnkd-20260331.htm)) |
| July 23, 2026 | [Furosemide FDA approval](https://sec-api.dev/pdufa/furosemide) | MNKD | edema | completed, approved | "On July 23, 2026, the U.S. Food and Drug Administration approved Furoscix ReadyFlow™ (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm)) |
| July 26, 2026 | [Furosemide PDUFA date](https://sec-api.dev/pdufa/furosemide) | MNKD |  | completed, approved | "FDA accepted for review a supplemental New Drug Application (sNDA) for Furoscix ReadyFlow Autoinjector; with a PDUFA target action date of July 26, 2026; if approved, it would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526073509/mnkd-ex99_1.htm)) |
| July 26, 2026 | [MANNKIND CORP PDUFA date](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | scheduled | "Furoscix ReadyFlow Autoinjector PDUFA date July 26, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-ex99_1.htm)) |
| August 5, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/mnkd-ex99_1.htm)) |
| November 5, 2026 | [MANNKIND CORP earnings report](https://sec-api.dev/companies/mnkd/catalysts) | MNKD |  | completed | "MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/899460/000119312526449743/mnkd-ex99_1.htm)) |
| March 2027 | [Technosphere insulin primary completion](https://sec-api.dev/pdufa/technosphere-insulin) | MNKD | Type 1 Diabetes Mellitus | scheduled | "NCT07224321 (INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07224321)) |
| Mar to Jun 2027 | [Technosphere insulin topline data readout](https://sec-api.dev/pdufa/technosphere-insulin) | MNKD | Type 1 Diabetes Mellitus | scheduled | "NCT07224321 (INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07224321)) |
| Dec 2027 to Mar 2028 | [Nintedanib dry powder inhalation topline data readout](https://sec-api.dev/pdufa/nintedanib-dry-powder-inhalation) | MNKD | Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07679893 (Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07679893)) |
| December 2027 | [Nintedanib dry powder inhalation primary completion](https://sec-api.dev/pdufa/nintedanib-dry-powder-inhalation) | MNKD | Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07679893 (Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Mannkind Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07679893)) |

## Drugs

- [Afrezza (afrezza)](https://sec-api.dev/pdufa/afrezza): 
- [Clofazimine](https://sec-api.dev/pdufa/clofazimine): 
- [Clofazimine inhalation suspension](https://sec-api.dev/pdufa/clofazimine-inhalation-suspension): MAC Lung Disease
- [Furosemide](https://sec-api.dev/pdufa/furosemide): edema
- [Afrezza (insulin recombinant human)](https://sec-api.dev/pdufa/insulin-recombinant-human): 
- [Nintedanib dry powder inhalation](https://sec-api.dev/pdufa/nintedanib-dry-powder-inhalation): Idiopathic Pulmonary Fibrosis
- [Technosphere insulin](https://sec-api.dev/pdufa/technosphere-insulin): Type 1 Diabetes Mellitus
- [V-Go (v-go)](https://sec-api.dev/pdufa/v-go): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mnkd/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MNKD catalysts: MANNKIND CORP PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mnkd/catalysts

```bibtex
@misc{secapidev_companies_mnkd_catalysts_20261116,
  title        = {MNKD catalysts: MANNKIND CORP PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mnkd/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mnkd_catalysts_20261116","title":"MNKD catalysts: MANNKIND CORP PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mnkd/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
